Form 4 for PHIO Phio Pharmaceuticals Corp.
Accepted 2023-07-05 00:00:00 ET · period of report 2023-06-30 · accession 0001209191-23-041254 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-07-05 | 2023-06-30+ | PHIO | Bitterman Robert J | Pres, CEO, Dir | P - Purchase | $2.86 | +2,000 | 18.2K | +12% | +$5,720 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common stock, $0.0001 par value | 2023-07-01 | P | A | 1,000 | $2.84 | 19,211 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. |
| 2 | Common | Common stock, $0.0001 par value | 2023-06-30 | P | A | 1,000 | $2.88 | 18,211 | D | — | — | (F1) Includes shares of common stock underlying unvested restricted stock units. |